Back to top
more

MEDIFAST (MED)

(Delayed Data from NYSE)

$18.60 USD

18.60
318,956

-0.23 (-1.22%)

Updated Aug 29, 2024 04:00 PM ET

After-Market: $18.58 -0.02 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Food - Miscellaneous

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sysco's (SYY) Latest Move to Enhance Delivery to Aid Growth

by Zacks Equity Research

Sysco (SYY) and Daimler Truck North America unveil a Letter of Intent to allocate up to around 800 battery electric Freightliner eCascadia Class 8 tractors to cater to Sysco's U.S. customers by 2026.

Kimberly-Clark's (KMB) Saving Efforts Aid Amid Rising Costs

by Zacks Equity Research

Kimberly-Clark's (KMB) efficient cost-saving efforts are yielding amid rising input costs. Also, the company is committed to its three key strategic growth pillars.

Service Corporation (SCI) Stock Appears Promising: Here's Why

by Zacks Equity Research

Service Corporation (SCI) has been gaining on its robust Funeral segment sales and its focus on expansion.

Mondelez (MDLZ) Troubled by Cost Inflation, Supply-Chain Woes

by Zacks Equity Research

Mondelez (MDLZ) has been encountering inflation in input costs and supply-chain bottlenecks. Management cuts its EPS growth forecast due to cost inflation.

Tyson Foods (TSN) Gains on Solid Brands & Capacity-Expansion

by Zacks Equity Research

Tyson Foods (TSN) is undertaking several operational and supply chain efficiency programs to place itself better for the long run.

Zacks.com featured highlights include Imperial Oil, CF Industry Holdings, The Chemours, Medifast, and APA

by Zacks Equity Research

Imperial Oil, CF Industry Holdings, The Chemours, Medifast, and APA are part of Screen of the Week article.

Sysco (SYY) Looks Promising: Stock Up More Than 10% in 6 Months

by Zacks Equity Research

Sysco Corporation (SYY) has been gaining on its Recipe for Growth plan and solid food-away-from-home trends.

Rimmi Singhi headshot

5 High Earnings Yield Value Picks Amid Market Jitters

by Rimmi Singhi

Value investing should be one of the most effective investment approaches now. IMO, CF, CC, MED and APA are some high earnings yield value stocks to tide over market mayhem.

McCormick (MKC) Stock Up More Than 15% in 6 Months: Here's Why

by Zacks Equity Research

McCormick (MKC) is benefiting from a robust recovery in the away-from-home demand. The company's prudent buyouts are yielding.

Are Investors Undervaluing MEDIFAST (MED) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

B&G Foods (BGS) Troubled by Cost Inflation, Supply-Chain Woes

by Zacks Equity Research

B&G Foods (BGS) has been encountering industry-wide inflation in input costs and supply-chain bottlenecks. Management cuts its adjusted EBITDA and EPS forecast due to cost inflation.

General Mills (GIS) TNT Crust Buyout to Fuel Accelerate Strategy

by Zacks Equity Research

General Mills (GIS) to acquire TNT Crust by first-quarter fiscal 2023. The move fortifies the company's position in the fast-growing away-from-home frozen baked goods category.

Mondelez (MDLZ) Growth Strategy Includes Portfolio Focus & More

by Zacks Equity Research

Mondelez International (MDLZ) updates the progress of its long-term strategy on its Investor Day. Also, the company updates its long-term organic net revenue growth algorithm to 3-5%.

3 Reasons Why Medifast (MED) Is a Great Growth Stock

by Zacks Equity Research

Medifast (MED) could produce exceptional returns because of its solid growth attributes.

Medifast (MED) Tops Q1 Earnings & Sales Estimates, Raises View

by Zacks Equity Research

Medifast's (MED) first-quarter 2022 results reflect increased earnings and revenues owing to continued strength in OPTAVIA. Management raises sales and earnings view for 2022.

Medifast (MED) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Medifast (MED) delivered earnings and revenue surprises of 0.84% and 0.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Things to Note as Medifast (MED) Lines Up for Q1 Earnings

by Zacks Equity Research

Medifast's (MED) first-quarter results are likely to reflect gains from the OPTAVIA lifestyle solution and coaching support system, whereas high costs are a concern.

Conagra Brands (CAG) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Conagra Brands (CAG) delivered earnings and revenue surprises of 1.75% and 2.74%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Troubled by High SG&A Costs, Gross Margin Woes

by Zacks Equity Research

Medifast (MED) has been seeing high SG&A expenses for a while now, mainly due to higher OPTAVIA commission costs. The company's gross margin has also been under pressure.

Sprouts Farmers (SFM) Q4 Earnings Beat, Sales Decline Y/Y

by Zacks Equity Research

Sprouts Farmers' (SFM) fourth-quarter 2021 comparable store sales decline 1.1% year over year. For 2022, management forecast comparable store sales growth to be 0-2%.

Keurig Dr Pepper (KDP) Q4 Earnings In Line, Sales Surpass

by Zacks Equity Research

Keurig Dr Pepper's (KDP) Q4 results gain from solid consumer demand and improvement in the away-from-home channel. Management issues an upbeat 2022 view.

Beyond Meat (BYND) Q4 Loss Wider Than Expected, Stock Down

by Zacks Equity Research

Beyond Meat's (BYND) fourth-quarter 2021 results reflect lower sales and a wider loss compared with the year-ago period. Soft U.S. retail demand due to the pandemic is a downside.

Medifast (MED) Q4 Earnings Beat, Strength in OPTAVIA Key Driver

by Zacks Equity Research

Medifast's (MED) fourth-quarter 2021 results reflect stellar earnings and revenues, courtesy of continued strength in OPTAVIA. Sales and earnings view for 2022 reflect year-over-year growth.

Medifast (MED) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Medifast (MED) delivered earnings and revenue surprises of 8.99% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Mondelez (MDLZ) Outlines Growth Strategy for AMEA Region

by Zacks Equity Research

Mondelez International (MDLZ) outlines its strategy for the Asia Pacific, Middle East & Africa region at the CAGNY Conference. It has core strategies designed to fuel sustainable growth there.